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1. Introduction 
The epidermal growth factor receptor (EGFR) is the prototypical receptor tyrosine kinase. It 
is localized to the plasma membranes of cells with an extracellular ligand binding domain 
and an intracellular kinase domain. Through the binding of extracellular ligands, the 
receptor undergoes a conformational change that alters the biochemical properties of 
proteins (effectors) within the cell. Ultimately, these changes result in modulation of the rate 
of cell growth, protein and DNA synthesis, cell motility, and cell proliferation. The EGFR is 
necessary for the proper development of organisms, as indicated by the fact that genetic 
knockout of the receptor results in animals that are embryonic lethal or die shortly after 
birth. This developmental role is also observed in adult animals, as pharmacological 
inhibition of the EGFR disrupts tissue homeostasis. 
In addition to these developmental roles, there is a strong association between 
overexpression and/or hyperactivation of the EGFR and cancer. Currently, there are several 
small molecule inhibitors and neutralizing, humanized antibodies against the EGFR that 
successfully treat EGFR-positive cancers (i.e. non-small cell lung carcinomas, colon, and 
head and neck cancers). Breast cancer is among those cancers that are characterized by 
enhanced EGFR levels and activity. However, the aforementioned pharmacologic agents 
have been of little success in the treatment of breast cancers. Therefore, a more detailed 
understanding of the cellular and molecular biology of EGFR function is required in order to 
successfully attenuate the growth and metastasis of EGFR-positive cells. 
Cells have numerous endogenous mechanisms to that regulate the specificity and duration 
of EGFR signaling. Endogenous regulatory mechanisms are logical pharmacological targets 
to inhibit EGFR activity because of their intrinsic ability to modulate signaling. One of the 
most important regulators of EGFR signaling is the endocytic pathway. The endocytic 
pathway can control both the duration of signaling and the spatial placement of the 
receptor. Historically, endocytosis has been considered a mechanism for the negative 
regulation of EGFR, as it decreases the number of cell surface receptors and inactivates the 
ligand:receptor complex by targeting it for lysosomal degradation. More recently, it has 
been appreciated that signaling of the EGFR varies based on the subcellular localization of 
the receptor. Specifically, in a given cell, the liganded EGFR can promote cell proliferation at 
some cellular locations (i.e. plasma membrane), whereas at others (i.e. the limiting 
membranes of endosomes) the receptor can induce apoptosis. Thus, a potential molecular 
etiology of EGFR overexpression in transformed cells is disrupted normal endocytic 
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trafficking of the EGFR. Slowed kinetics of receptor degradation will increase the steady-
state levels of the EGFRs over time. If this hypothesis holds true, the endocytic pathway is a 
logical target for pharmacological manipulation to prevent the progression of such cells.  
This chapter will explore the basic cell biology of the EGFR and the endocytic mechanisms 
that regulate its signaling. To be discussed are the workings of the endocytic pathway, 
strategies used to understand the relationship between endocytic trafficking and EGFR 
signaling, and data indicating how trafficking regulates signaling. These mechanisms will be 
dissected and potential points for attenuating the enhanced EGFR activity will be discussed. 
2. The EGFR 
The EGFR is an approximately 180 kDa transmembrane protein that is oriented on the 
plasma membrane such that the amino terminus half of the protein is extracellular and the 
carboxyl terminus portion is intracellular. Thus, by virtue of its orientation, the amino 
terminus of the EGFR detects and binds ligands; the carboxyl terminal kinase domain 
converts the conformational change induced through ligand binding into intracellular, 
biochemical signals. The EGFR is also known as ErbB1, and is part of the larger ErbB family 
of receptor tyrosine kinases that is comprised of ErbB1, ErbB2, ErbB3 and ErbB4. This family 
shares many features such as membrane topology, mechanism of activation and signaling, 
and downstream effectors. However, each member is unique in its tissue expression, its 
activating ligands, magnitude and duration of effector signaling, and membrane trafficking 
(Hynes and MacDonald, 2009). 
There have been seven ligands that have been reported to be able to activate the EGFR – 
epidermal growth factor (EGF), heparin binding epidermal growth factor (HB-EGF), 
betacellulin (BTC), transforming growth factor- (TGF-), amphiregulin (AR), epiregulin, 
and epigen (Harris et al., 2003). The regulated secretion of these ligands is an important 
determinant of when a receptor gets activated. Further, overexpression of certain ligands, 
namely TGF-, has been associated with an increase in receptor activity and enhanced cell 
proliferation (Matsui et al., 1990; Sandgren et al., 1993). 
Based on the available data, it is commonly held that all ligands initiate signaling in the 
same fundamental manner (Figure 1). Briefly, ligand binding to an EGFR monomer induces 
a conformation change in the receptor that exposes a dimerization motif (cysteine rich 
domain). Through association with another EGFR or related family member (ErbB2, ErbB3, 
or ErbB4), a dimeric receptor forms, and initiates activation of the intracellular kinase 
domain (Dawson et al., 2005). In turn, the kinase domain phosphorylates tyrosine residues 
on the very carboxyl terminus of the protein. These newly formed phosphotyrosines serve 
as docking site for downstream signaling molecules (effectors). The EGFR-stimulated 
effector activity alters the intracellular biochemistry and results in cellular changes, such as 
cell proliferation, differentiation, and migration. 
There is a long list of effector molecules reported to be downstream of the activated EGFR. 
Two of the major questions for scientists that study EGFR biology and pathology are 1) to 
identify which receptor:effector interactions occur under physiological and pathological 
conditions and which ones are an artifact of cell culture models and 2) to determine which 
effectors are necessary and sufficient for a specific cell physiology/pathology. Asking these 
questions is confounded by the fact that receptor:effector interactions can arise as an 
unintended consequence of receptor overexpression. This is true in model systems that are 
generated by the scientist as well as naturally occurring cell transformation. As discussed  
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Fig. 1. Schematic of EGFR Activation. Binding of one of the EGFRs endogenous ligands 
induces a conformational change in the receptor that permits dimerization and kinase 
activity. Kinase active receptor than transphosphorylates the receptor with which it is 
associating. The resulting phosphotyrosines serve as docking sites for down stream 
signaling molecules. 
below, many cancers are characterized by overexpression of the EGFR. Therefore, 
interactions that do not occur in a biological setting may be very relevant in a pathological 
condition. 
There are numerous lines of evidence that indicate the EGFR plays important physiological 
roles in tissue development and homeostasis (Jorissen et al., 2003). It is expressed on the 
surface of virtually every cell in the body. Mice that have been engineered to knock out the 
EGFR gene are either embryonic lethal or die shortly after birth, indicating its role in pre-
natal development (Miettinen et al., 1995; Sibilia and Wagner, 1995; Threadgill et al., 1995). 
Patients taking EGFR inhibitors as part of an anti-cancer chemotherapeutic regimen, 
experience complications such as colitis, dermatitis, and corneal abrasions, indicating the 
receptor contributes to the homeostasis of those tissues (Tullo et al., 2005; Zhang et al., 2007). 
This is supported by the genetically engineered deletion of EGFR ligands (i.e. EGF, 
transforming growth factor- (TGF-), or amphiregulin) have revealed roles in maintaining 
development of tissue, such as mammary glands, eyes, hair, and epidermis (Luetteke et al., 
1999) and provide evidence of the receptors’ role in tissue homeostasis. 
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3. EGFRs in cancer 
In addition to roles in tissue development and homeostasis, the driving force behind the 
study of the EGFR has been its role in cancer. The EGFR is overexpressed and/or 
hyperactivated in many cancers including, but not limited to, cancers of the breast, ovary, 
colon, lung, head and neck, pancreas, and brain (Rowinsky, 2004). Further, overexpression 
of the EGFR in many cancers correlates with poor patient prognosis (Nicholson et al., 2001). 
There are a number of events that can cause the increase in EGFR activity that is associated 
with cancer. These include gene amplification, activating mutations of the receptor’s kinase 
domain, and deletions of the extracellular domain that regulate the receptor’s ligand-
binding dependent activity (Hynes and MacDonald, 2009; Uberall et al., 2008). Despite this 
strong association, it remains unclear whether overexpression/hyperactivation of the EGFR 
is the root cause of cell transformation or a cell becoming transformed is what leads to the 
overexpression/hyperactivation of the EGFR.  
Regardless of the cause of increased EGFR activity, there are several anti-cancer therapies 
that specifically target the EGFR that have been approved by the United States Food and 
Drug Administration (FDA). These drugs fall in two classes. First, humanized monoclonal 
antibodies target the extracellular portion of the receptor and antagonize the binding of 
endogenous EGFR ligands. These antibodies are 528 mouse IgG2a, the 225 mouse IgG1, and 
the C225 humanized monoclonal antibody. The second class of drugs are small molecule 
inhibitors of the EGFR kinase domain [Iressa (gefitinib) and Tarceva (erlotinib)]. Both classes 
of drugs are able to prevent the progression of cancer by inducing apoptosis specifically in 
those cells with increased EGFR activity. Therapeutic use of these drugs has been approved 
for non-small-cell lung cancer, squamous cell carcinoma of the head and neck, and colorectal 
cancers (Baselga and Arteaga, 2005).  
One issue that remains unresolved is the limited therapeutic efficacy of EGFR inhibitors in 
the treatment of breast cancers. This is true, despite the fact that EGFR overexpression is 
associated with some breast cancers. To date, only Tykerb (lapatinib) is approved for the 
treatment of breast cancer. However, it should be noted that Tykerb inhibits both the EGFR 
and its receptor tyrosine kinase family member, ErbB2, and is only approved for use in 
conjunction with the aromatase inhibitor Femara (letrozole) (Cameron et al., 2010). Despite 
the limited success of EGFR inhibitors in treating breast cancers, the evidence from other 
cancers indicates the receptor still has potential as a therapeutic target. In order to develop 
better anti-cancer chemotherapeutic agents that target the EGFR in breast cancer, a more 
detailed understanding of EGFR signaling is required. 
4. EGFR endocytic pathway 
Not only are the effectors with which the EGFR interacts important, but also the quality of 
interaction. Both the duration and magnitude of effector activity are what determine how 
cell physiology is modified. A tremendous body of literature supports the idea that the 
regulation of signaling is the critical determinant in how receptor specific signals are 
produced. This is the most logical explanation for how a number of different cell surface 
receptor (i.e. EGFR, insulin receptor, and platelet derived growth factor receptor) can share 
an overlapping set of effector molecules, yet each produces a receptor-specific change in cell 
physiology. 
One of the principle mechanisms by which EGFR signaling is regulated is ligand-mediated 
endocytosis. Internalization of the EGF:EGFR complex can be either clathrin-dependent or 
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clathrin-independent. Clathrin-dependent endocytosis is the most well studied as it is the 
predominant route of receptor internalization in response to physiological concentrations of 
ligand. 
By all accounts, all of the endogenous EGFR ligands can promote internalization of the 
EGFR, through a series of well-defined steps (Figure 2). Following binding of ligand, the 
ligand:receptor complex translocates along the plasma membrane to a domain that is 
enriched on the intracellular face with clathrin. The clathrin lattice invaginates to form a 
clathrin-coated pit that pinches off generating an intracellular clathrin-coated vesicle. Once 
inside the cell, clathrin is shed from the vesicle, giving rise to an intermediate vesicle. The 
intermediate vesicle fuses with and delivers the ligand:receptor complex to the early 
endosome. This compartment is where sorting of the cargo occurs. The predominant route 
of trafficking of the EGF:EGFR complex is into a late endosome/multivesicular body, by 
way of vesicle maturation. Alternative routes include recycling to the plasma membrane, 
trafficking to the nucleus, and delivery to the endoplasmic reticulum (Liao and Carpenter, 
2007; Masui et al., 1993; Wang et al., 2010). For those receptors that get delivered to the late 
endosome/multivesicular body, that compartment fuses with the lysosome that degrades 
the ligand and receptor in the protease rich environment. 
Each endocytic compartment has a number of distinguishing features. First, as the 
compartments get further away from the plasma membrane, they become more acidic and 
increase in density. In addition, each endocytic location has a unique protein composition. 
These three features have proven to be important in understanding ligand:receptor 
interactions, receptor trafficking, and receptor signaling. Further, researchers continue to 
utilize these features to distinguish one compartment from another. For instance, the 
different densities of the endosomes can be use to separate compartments by sedimentation 
centrifugation (Vanlandingham and Ceresa, 2009). Endosome specific proteins can be used 
as markers to identify which intracellular compartment the receptor resides 
(Vanlandingham and Ceresa, 2009).  
It is important to note that following endocytosis, not all ligands target the EGFR for 
lysosomal degradation. A recent, comprehensive study of the trafficking of EGFR ligands 
was performed using human laryngeal carcinoma (Hep2) cells as a model (Roepstorff et al., 
2009). In this study, six of the endogenous EGFR ligands were analyzed for their ability to 
induce receptor internalization, lysosomal degradation, and recycling. Following ligand 
treatment, the authors used indirect immunofluorence to monitor receptor co-localization 
with early and late endosome markers [early endosome autoantigen 1 (EEA1) and Lysosome 
associated membrane protein 1 (Lamp1)]. In addition, biochemical assays were used to 
assess the kinetics of ligand stimulated EGFR degradation and recycling. The data from the 
manuscript indicate that two ligands TGF- and epiregulin lead to receptor recycling. HB-
EGF and betacellulin, like EGF, target the receptor for degradation. Interestingly, 
amphiregulin treatment yields a phenotype that is somewhere in between – recycling with 
slower kinetics. 
While the molecular basis for these differences in receptor trafficking are not entirely clear 
for all ligands, one ligand has been particularly well studied, particularly in the context of 
cancer. As stated above, treatment with TGF- induces EGFR internalization and recycling 
to the plasma membrane. Once back at the plasma membrane, the receptor can be re-
stimulated with available ligand and another round or signaling can occur (McClintock and 
Ceresa, 2010). The question becomes: what are the properties of TGF- that promote  
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Fig. 2. Schematic of EGFR Endocytic Trafficking. 
receptor recycling, whereas EGF (and others) does not? It is widely held that the difference 
lies in the pH sensitivity of ligand binding. Both EGF and TGF-α bind the EGFR with 
comparable affinity at neutral, physiological pH (pH 7.3-7.4). At pH 6.8, 50% of TGF- will 
dissociate from the receptor. EGF requires a pH of 5.9 for 50% of ligand dissociation (Rutten 
et al., 1996). This is biologically important because the pH of the early endosome is ~6.8 
(Gruenberg and Maxfield, 1995), therefore significant dissociation occurs. The loss of ligand 
likely converts the receptor back into a kinase-inactive conformation and is accompanied by 
dephosphorylation of the receptor. This would prevent association with the c-Cbl ubiquitin 
ligase that ubiquitylates the receptor, thereby targeting it to the lysosome for degradation.  
Since EGFR endocytosis frequently culminates in the targeted destruction of the 
ligand:receptor complex in the lysosome, it is logical to assume this route of membrane 
trafficking would negatively regulate signaling. However, the role of endocytosis is more 
complex. Data exist that support the endocytic pathway positively regulating EGFR signaling, 
as well. It is clear that endocytic trafficking provides temporal regulation of receptor signaling.  
4.1 Endocytosis as a negative regulator of EGFR signaling 
Formal proof that endocytosis negatively regulates EGFR signaling came from the 
laboratory of Michael Rosenfeld (Wells et al., 1990). In order to understand the role of 
endocytosis in signaling, Wells et al. generated mutant EGFRs that were deficient in the 
ability to internalize. They stably expressed these receptors in NR6 cells (derived from 
NIH3T3 cells) that are devoid of endogenous EGFRs. Once they established that ligand 
mediated endocytosis of these receptors was blocked, they examined EGF-mediated cell  
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transformation using a colony formation assay. A dose response curve of EGF-mediated cell 
transformation revealed the EGFRs defective in the ability to internalize required lower 
doses of EGF to undergo transformation and produced more transformed cells. From these 
data, it was generally accepted that endocytosis is a negative regulator of EGFR signaling. 
There have been numerous of additional lines of evidence to support this model, particular 
in cancer models. Importantly, several come from naturally occurring cancers. For instance, 
one common EGFR mutation, EGFRvIII, demonstrates the relationship between receptor 
internalization and signaling. EGFRvIII is associated with cancers of the brain, lung, 
prostate, and ovary. The receptor itself is a truncation mutant that is devoid of amino acids 
6-273, which encompasses the ligand binding domain and dimerization arm (Wikstrand et 
al., 1995). Grandal et al. compared the levels of internalization and receptor phosphorylation 
in NR6 cells expressing either EGFRvIII or wild type EGFR (Grandal et al., 2007). While 
EGFRvIII can be internalized, its rate of degradation is much slower than the EGFR. These 
delayed kinetics correspond to prolonged signaling. While the authors do not perform a 
detailed analysis of signaling, there is clearly enhanced signaling based on their association 
with cancer. 
A second example demonstrates how other ErbB family members can both delay EGFR 
degradation and enhance its signaling. Like the EGFR, ErbB2 is frequently overexpressed in 
cancers, notably breast cancers (Guerin et al., 1988). Several groups have examine how 
ErbB2 (and other ErbB family members) impinge on EGFR trafficking. Worthylake et al. 
performed a detailed biochemical characterization of EGFR ligand binding, cell surface 
expression, recycling and degradation with and without ErbB2 present (Worthylake et al., 
1999). Using mammary epithelial cells (MTSV1 and derivative lines) as a model, they 
examined the EGFR and ErbB2 when the two receptors were expressed at a 9:1 and 1:1 ratio. 
One of their major findings was that ErbB2 inhibits the downregulation of the EGFR. 
Similarly, Offterdinger and Bastiaens examined if expression of ErbB2 affected the signaling 
of the EGFR (Offterdinger and Bastiaens, 2008). Using Chinese Hamster Ovary (CHO) cells 
that express EGFRs, but low levels of ErbB2, the authors stably transfected the cells with 
ErbB2. Using single cell assays, the two cells line were transiently transfected with an EGFR 
that had been tagged with green fluorescent protein (GFP). With this model, they observed 
expression of ErbB2 attenuated the rate of EGFR-GFP internalization, it also prolonged the 
phosphorylation of the EGFR. Since kinase dead ErbB2 had similar affects on trafficking and 
signaling, the authors concluded that the increased phosphorylation was not due to ErbB2 
kinase activity, but rather decreased EGFR degradation/phosphorylation in the presence of 
ErbB2.  
Additionally, there are a number of cancers that have been associated with defects in the 
endocytic trafficking of the EGFR and other cell surface receptors. Mutations and deletions 
of proteins involved in trafficking have been reported to be associated with acute myeloid 
leukemia (AML), hepatocellular carcinomas (HCC), breast and prostate cancer (Mosesson et 
al., 2008). It general, these protein aberrations result in a delay in the kinetics of receptor 
degradation and yield a higher level of receptor signaling, consistent with endocytosis 
negatively regulating signaling. 
4.2 Endocytosis as a positive regulator of EGFR signaling 
In the last fifteen years, a second role for the endocytic pathway to regulate EGFR signaling 
has come to light. This secondary mechanism is the spatial regulation conferred by placing 
the active receptor in the same microenvironment as downstream signaling molecules (or 
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effectors). The first evidence for this came from the laboratory of Sandra Schmid. Vieira et al, 
expressed a dominant negative mutant of the large guanine nucleotide-binding protein, 
dynamin, in HeLa cells, which prevents endocytosis of the EGFR via clathrin-coated pits. 
EGFR stimulation of cells expressing this dominant negative protein retains the liganded 
EGFRs at the plasma membrane (Vieira et al., 1996). This approach removes the potential 
confounding effects of receptor mutagenesis or differences in expression levels in stable cell 
lines. The data from this study revealed that the activity from some effectors was enhanced 
when endocytosis blocked (EGFR phosphorylation, Shc, Grb2). Conversely, other effectors 
required endocytosis for maximal activity, namely, mitogen activating protein kinase 
(MAPK) and phosphatidyl inositol 3’-kinase (PI3K). This finding introduced the idea that 
endocytosis could be a positive regulator of signaling. 
This finding was not without controversy. Subsequent groups reported that the expression 
of dominant negative dynamin inhibited MAPK activity. Thus, it was suggested that the 
attenuated MAPK activity was not due to a failure of the active EGFR to reach the endosome 
and stimulate MAPK, but rather a dynamin-dependent activation of MAPK (Johanessen et 
al., 2000). In addition, it has been suggested that blocking normal endocytic trafficking may 
affect the ligand binding properties to the EGFR (Ringerike et al., 1998).  
However, since the initial report, there have been several additional lines of evidence that 
endocytosis provides spatial regulation to EGFR signaling. Two separate studies from the 
Lauffenburger’s group provide compelling support. To examine the spatial regulation of 
EGFR:effector interactions, the authors exploited the different trafficking itineraries used by 
TGF- as compared to EGF. By comparing the effects of the two ligands, they were able to 
alter the ratio of active EGFR at the plasma membrane and within the cell. They discovered 
that EGFRs at the plasma membrane preferentially activated phospholipase C1 (Haugh et 
al., 1999b). Although these data indicate that endocytosis negatively regulates PLC1 
activity, it also supports the idea that receptor:effector interactions are spatially regulated . 
Evidence that the spatial regulation of signaling is a positively regulator came from the 
follow-up publication. Using a similar approach, the authors were able to demonstrate that 
p21ras was actively activated from within the cell (Haugh et al., 1999a).  
The detailed kinetic analysis performed in these studies is not trivial. One of the strengths of 
this work is that the signaling is studied in the context of wild type EGFRs that are 
expressed at the physiological concentrations receptors (Chen et al., 1996). Further, there 
was not perturbation of the endocytic pathway. Thus, these data likely provide the most 
accurate snapshot of what occurs physiologically.  
Regardless of exactly how endocytic trafficking affects EGFR signaling, it is clearly an 
important mechanism. Understanding this process will undoubtedly generate important 
insights regarding the etiology of cancer and, potentially, the treatment of cancers.  
4.3 Deciphering the role of endocytosis in EGFR signaling 
There is plenty of direct and indirect evidence to indicate the endocytic trafficking regulates 
EGFR signaling, but a deeper understanding of the molecular mechanism is necessary. For 
instance, elucidating the molecular mechanism(s) will provide insight into how to specifically 
manipulate the pathway and modulate signaling as desired. There are a number of 
fundamental questions that need to be answered. Does endocytosis regulate EGFR signaling 
spatially, temporally, or both? Are the regulatory processes unique for individual cells and 
tissues? Do variations in receptor expression (as often occur in cancers) affect the regulation?  
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Temporal regulation of signaling refers to the duration of signaling, and would be consistent 
with endocytosis serving strictly as a negative regulator. How this might occur is not 
entirely clear. There has been much speculation in the literature whether this occurs by: 1) 
promoting receptor dephosphorylation, thereby eliminating its ability to interact with 
downstream effectors, 2) sequestration into the intraluminal vesicles of the late 
endosome/multivesicular body which prevents interactions with cytosolic effector proteins, 
or 3) degradation of the receptor. Alternatively, it may be that a combination of the three 
events (or possibly others) may contribute to signal attenuation. 
In contrast, if endocytosis provides spatial regulation to signaling, it could either positively 
or negatively regulate signaling, depending of the effector protein and its subcellular 
location. Spatial regulation suggests the co-localization of the receptor and effector. Since 
this could occur at any point along the pathway (i.e. plasma membrane, early endosome, late 
endosome), its effect on signaling could be positive or negative. If receptor:effector 
communication is occurring at the plasma membrane, then endocytosis negatively regulate 
those interactions; conversely, receptor:effector interaction at intracellular locales, such as 
the early endosome, would be positively regulated by endocytosis. 
It is important to note that the model of spatial regulation of EGFR signaling is predicated 
on the fact that there is compartmentalization of effector proteins. Only if an effector is 
concentrated at a given subcellular locale will endocytosis be able to confer specificity. If an 
effector is ubiquitously expressed throughout the cell, either in normal or pathological 
conditions, then spatial regulation cannot be achieved. This is an important consideration 
when examining cancer cells with aberrant protein expression. The unregulated signaling 
may be a consequence of lost spatial regulation of signaling. 
As mentioned above, it cannot be ruled out that the endocytic pathway plays both positive 
and negative roles, depending on the effector. In fact, such a model may help explain the 
diversity in the cell biology that can be mediated by the receptor. For instance, signals that 
promote cell migration may be negatively regulated by endocytosis whereas those that 
control cell proliferation may require endocytosis. 
Understanding the contribution of the endocytic pathway to EGFR signaling has important 
implications for a number of reasons. First, it will reveal the fundamental mechanisms of cell 
surface receptor signaling. It is likely this regulatory process is not unique to the EGFR or 
receptor tyrosine kinases. Thus, understanding this regulatory process has implications for 
other cell surface receptors and may guide the development of novel therapeutic agents for 
diseases other than cancer. Second, understanding the molecular mechanisms that regulate 
EGFR signaling will provide potentially useful clues to how the EGFR contributes to the 
pathology that underlies many cancers. These findings may provide new insights into the 
causes and potential prevention of cancer. Finally, the intricacies of signaling need to be 
appreciated in order to develop novel therapeutics that target the EGFR. Currently, the 
EGFR inhibitors (antibodies and tyrosine kinase inhibitors) are only effective against a 
subset of EGFR-positive cancers. A better of understanding of EGFR signaling will aid in the 
targeted design of therapeutics for a broader spectrum of cancers.  
5. Strategies for deciphering the role of endocytic trafficking in EGFR 
signaling 
Membrane trafficking and signal transduction are two very dynamic processes. Studying 
these events in real time has proven difficult. As a result, most investigators use a strategy of 
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disrupting endocytic trafficking or at least dramatically slowing it, and determining how 
signaling is affected. To this end, investigators have relied heavily on two fundamentally 
different strategies: mutagenesis of the receptor itself or perturbation of the endocytic 
pathway. Here we discuss the basic components of these strategies and the strengths and 
weaknesses of each approach. 
5.1 Receptor mutagenesis to inhibit EGFR endocytic trafficking 
Endocytosis-deficient, mutant EGFRs allows one to examine the EGFR directly, without 
disrupting proteins that are also used by other receptors that share the endocytic pathway. 
Therefore, the effects seen in response to EGF treatment are truly from the EGFR and do not 
represent a change in the fundamental properties of the cell. One technical limitation to this 
approach is that in order to accurately study two different receptor populations (i.e. wild type 
and an endocytosis–deficient mutant), the two receptors need to be stably expressed in cells 
that are devoid of the EGFRs. First, all cell line are not amenable to stable transfection, 
therefore the repertoire of cell lines can be limited. Second, in making stable cell lines, it is 
difficult to control the level of protein expression. Differences in receptor expression will affect 
the total level of activated receptor in response to ligand as well as number of effectors that are 
activated downstream. Thus, it could be hard to determine if the difference in signaling reflect 
changes in endocytic trafficking or receptor expression. Finally, as with all mutagenesis 
strategies, there is the potential that mutation of the receptor inhibits one function (such as 
endocytosis), there will an unexpected change in another (for instance, signaling). 
In addition to the technical limitations to using mutant EGFRs, there is an even greater 
biological limitation. The molecular mechanisms the regulate EGFR endocytic trafficking are 
complex and multi-faceted. Despite the EGFR being arguably the most studied receptor in 
the field of endocytic trafficking, there are constantly new mechanisms of internalization 
being identified. Often newly discovered mechanisms are redundant with a previously 
identified mechanisms. The multiple mechanisms for regulating internalization are 
consistent with the notion EGFR endocytosis is critical to the proper function of the cell. 
The complexity of EGFR endocytosis is illustrated by a recent study by Goh et al. (Goh et al., 
2010). In this study, the authors used a combination of receptor mutagenesis and RNA 
interference (RNAi) to completely block EGFR endocytosis in porcine aortic endothelial 
(PAE) cells. PAE cells were chosen because they do not express the EGFR or any of its ErbB 
family members. Ultimately, the authors demonstrate that there are at least four completely 
redundant or partially interrelated mechanisms for EGFR endocytosis. When all four 
processes were targeted, the result was a signaling-capable EGFR with normal kinetics of 
kinase activation and tyrosine phosphorylation.  
5.2 Disruption of endocytic trafficking by inhibition of stage-specific regulatory 
proteins 
An alternative approach for understanding how the endocytic pathway affects EGFR 
signaling is to disrupt the machinery that guides the ligand:receptor complex through the 
endocytic pathway. Entry and exit from each endocytic location is highly regulated by a set 
of proteins that are unique for that endocytic stage. Knock down or expression of dominant 
negative forms of those proteins can be used to alter EGFR trafficking. For instance, as 
described above, internalization of the receptor is regulated by the large GTPase dynamin. 
Expression of dominant negative dynamin (Damke et al., 1994) or knock down of dynamin 
expression by RNAi (Huang et al., 2004) prevents EGFR endocytosis.  
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It should be noted that there are several proteins that are required for the internalization of 
the EGFR. Expression of dominant negative mutants or knock down of many of these 
proteins of proteins will impair the kinetics of EGFR endocytosis. For instance, work by the 
Sorkin laboratory has shown that knock down of clathrin heavy chain, Grb2, and dynamin II 
will all cause a decrease in EGFR endocytosis to some extent (Huang et al., 2004). Further, 
since each step along the endocytic pathway is regulated by a variety of small molecular 
weight G-proteins, endosomal sorting complex required for transport (ESCRT), and adaptor 
proteins, the activity and expression of these proteins can also be targeted to inhibit 
intracellular trafficking. Considerable work has been done analyzing how the RAB family of 
proteins contributes to EGFR trafficking; therefore modulation of RAB expression or activity 
can alter movement of the receptor into and out of various endocytic compartments (Ceresa, 
2006). 
While this approach eliminates the complications like variable levels of receptor expression 
and potential conformational changes in the receptor, there are other caveats. First, many of 
the proteins used to regulate EGFR endocytic trafficking are shared with other receptors. 
Therefore, knocking down at protein to prevent EGFR endocytosis, will likely affect the 
internalization of other receptors. This likely will not be a problem if the focus is on 
receptor:effector communication, because the basal activity can be established by examining 
cells in the absence of an EGFR ligand. However, the analysis of whole cell physiology may 
be more complex, depending on what receptors are present in the cell, their basal activity, 
and the cell physiology that is being examined. Second, one must keep in mind that 
disrupting endocytic trafficking, only inhibits the kinetics of the pathway. It is not an 
absolute block. Therefore, receptors may accumulate at one endocytic stage, but in all 
likelihood, still be able to proceed to the next compartment, albeit at a dramatically slowed 
rate. 
The third issue is more likely to be a problem. Disrupting endocytic trafficking can alter the 
steady-state distribution of the receptor . It is often under appreciated that the EGFR 
internalizes in the absence of ligand, albeit at a much slower rate than in the presence of 
ligand. Approximately, 2-3% of the EGFR constitutively internalizes every minute. 
Following internalization, these unliganded receptors recycle back to the plasma membrane 
(Herbst et al., 1994).  
The cause of unliganded EGFR internalization has not been determined experimentally, but 
may reflect receptors that spontaneously form an “active” conformation in the absence of 
ligand or receptors that randomly localize to a clathrin enriched membrane domain as the 
clathrin-coated pit forms. While the molecular determinants guiding unliganded receptors 
to internalize is not fully understood, it is clear that unliganded and liganded EGFRs 
trafficking through the same endocytic machinery. Therefore, when the endocytic trafficking 
is disrupted, receptors that constitutively internalize will accumulate within the endocytic 
pathway where the block is in place. This may, or may not, affect the total number of EGFRs 
in the cell. However, it has been shown for mutants of RAB5 to change the amount of cell 
surface EGFR (Dinneen and Ceresa, 2004).  
This caveat is particularly important when using strategies that block receptor 
internalization (i.e. knock down of dynamin, clathrin heavy chain, Grb2), as an increase in 
cell surface receptors may result. In this case, one would need to be cautious when enhanced 
signaling is observed to determine whether it is the result of the block in endocytosis or 
increased number of ligand:receptor complexes. Similarly, if reagents were used to block  
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Fig. 3. Summary of Different Strategies Used to Study the Relationship between EGFR 
Endocytic Trafficking and Signaling. 
endocytic trafficking within the cell (i.e. knock down of RAB5, RAB7, or TSG101), there may 
be an intracellular accumulation of receptors and a decrease in cell surface receptors. Under 
this scenario, the challenge is to understand whether decreases in signaling are due to the 
endocytic trafficking or decreased ligand:receptor complexes. 
5.3 Pharmacological inhibitors of the endocytic machinery  
Pharmacological inhibitors of the endocytic pathway offer an alternative strategy for 
studying EGFR endocytic trafficking. There are a limited number of such agents available. 
To date, these compounds have been primarily used for studying endocytic trafficking. 
Only recently have they been used to study how trafficking affects signal transduction.  
As with most aspects of the endocytic pathway, the knowledge and reagents are greatest at 
the plasma membrane and decrease as one progresses to the lysosome. This is true for 
pharmacological inhibitors as well. At the plasma membrane, there are a number of 
pharmacological options available. One of the earliest strategies was intracellular potassium 
depletion. Work by Larkin et al. demonstrated that depletion of intracellular potassium 
reduced the formation of clathrin-coated pits and dramatically reduce low density  
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lipoprotein internalization (Larkin et al., 1983). This strategy is particularly attractive 
because the technique is relatively easy to perform and the endocytic inhibition is readily 
reversible. Since that report, other agents have been used including, chlorpromazine 
(inhibitor of clathrin assembly/disassembly) (Feugaing et al., 2007), monodansyl cadversine 
(Ray and Samanta, 1996), and most recently the dynamin inhibitor, dynasore (Hill et al., 
2009).  
One of the most well described inhibitors of intracellular trafficking is the ionophore, 
monensin. Monensin functions by inhibiting early endosome acidification. When monensin-
treated cells are incubated with EGF, the receptor accumulates in the early endosome, and 
rates of receptor degradation and recycling are dramatically reduced (King, 1984). A similar 
drug, bafilomycin, disrupts trafficking in a similar manner (Presly et al., 1997). Intracellular 
endocytic trafficking can also be inhibited by the anti-malarial drug, chloroquine. Due to its 
properties as a weak base, it accumulates in the lysosome and inhibits trafficking to that 
compartment (Anderson et al., 1984). 
5.4 Temperature reduction to inhibit endocytic trafficking  
Membrane trafficking is temperature dependent. Exploiting this property can be a useful, 
non-invasive strategy for disrupting endocytic trafficking. Carrying out experiments at 4°C 
will effectively reduce all endocytosis, whereas a 16°C incubation prevents movement out of 
the early endosome. Both inhibitions are reversible by restoring cells to physiological 
temperatures (37°C). Further, temperature reduction is readily applicable to all cells.  
Many of the same advantages of pharmacological inhibitors are seen with temperature 
reduction. The effects on membrane trafficking are rapid and reversible, which minimizes 
the changes in the steady-state distribution of the receptor. The biggest disadvantage is in 
studying EGFR-signaling. Most receptor:effector communication is temperature dependent. 
While receptor:effector interactions would likely still occur at lower temperature (although 
it would take longer to reach steady-state), the kinetics of activation would be altered, 
thereby making the interpretation of signaling difficult. 
As with most of cell biology, the best approach is multiple approaches. Complementing 
receptor mutagenesis and endocytic inhibitors will provide the strongest case that 
differences in signaling are due to changes in trafficking. 
6. Ligand based strategies for studying EGFR endocytosis  
Given the limitations of using a receptor based and a cell-based strategies, an alternative 
approach is to use a modified ligand to disrupt trafficking. An emerging strategy is to 
conjugate EGF (or another EGFR ligand) to an immobilized matrix. For instance, EGF can be 
covalently bound to polystyrene beads that are too large to internalize or a tissue culture 
dish. This strategy allows the ligand to bind and activate the receptor, but the conjugated 
matrix (polystyrene bead or tissue culture dish) physically impedes receptor internalization.  
There are several advantages to this approach. First, there is no limitation to what EGFR-
expressing cell type can be studied. This is particularly important since often times cell lines 
that are good models for studying EGFR endocytic trafficking are not good models for 
studying receptor signaling. In addition, previous methods favored the used of cell lines 
that are receptive to the introduction of cDNA, siRNA, and viral transduction. Second, since 
the endocytic inhibitor affects only liganded receptors, a homogenous population of  
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Approach Advantages Disadvantages 
Endocytosis Deficient, 
Mutant EGFR 
Specific for the EGFR Requires stable cell line 
Difficulty getting comparable 
receptor numbers 
Numerous endocytic processes 
  
Biochemical/Genetic 
Disruption of Endocytic 
Machinery 
Can examine endogenous 
receptors at 
physiological levels 
Can examine an array of 
endocytic locations 
Other cell surface receptors are 
affected 
Can change the steady-state 
distribution of EGFRs 
 Difficult to define endocytic 
compartments 
  
Pharmacological Inhibitors Act Quickly 
Can Use in a range of cell 
lines 
Questions of specificity on 
endocytic location 
Disrupt trafficking of multiple 
receptors 
  
Temperature Reduction Act Quickly 
Can Use in a range of cell 
lines 
Disrupt trafficking of multiple 
receptors 
Decreases Receptor and Effector 
enzyme activity 
  
Tethered Ligands Can Use in a range of cell 
lines 
Specific for activated EGFR 
May select for high affinity 
receptors 
Table 1. Advantages and Disadvantages to Various Methods for Studying EGFR Endocytic 
Trafficking. 
receptors is being examined, and there are no concerns that some receptors have escaped the 
endocytic inhibition. Finally, since the endocytic inhibitor is the ligand, there are no changes 
in the steady-state distribution of the receptor or compensatory mechanisms developed by 
the cell. 
The use of EGF-beads has some limitations as well. First, by design, the EGF-beads have 
multiple molecules of EGF bound to them. Therefore, there could be multiple ligand:receptor 
interactions with one EGF-bead. While this will not likely affect the kinetics of ligand 
association, the increased stability may affect the kinetics of ligand dissociation. This may 
affect the duration of ligand binding. Second, it is unknown how the conjugation process 
affects ligand binding and subsequent biological activity. As illustrated in Figure 4, the EGF 
molecule is conjugated to a carboxylate modified polystyrene bead via zero length crosslinker. 
Depending on which amino group is the site of conjugation that may affect the ability of the 
ligand to bind to the receptor. Although all studies using modified EGF clearly demonstrate at 
least some of the immobilized ligand retains its biological activity, it is not always clear to 
what extent. Finally, the bead itself has unintended consequences. While the large physical 
size of the bead provides a means for blocking entry through clathrin-coated pits, it may also 
sterically hinder the formation of EGF:EGFR complexes within a subdomain of the cell. 
At this point it is difficult to discern which issues are theoretical and which are practical. 
From a biochemical perspective, we attempted to circumvent these issues by comparing  
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Fig. 4. Schematic of the Synthesis of EGF-beads. 900 nm polystyrene beads modified with 
carboxylate groups are reacted with 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDAC) to form an active O-acylisourea intermediate that readily couples to 
the terminal amino group in EGF (Verveer et al., 2000). 
cells that had comparable levels of EGFR phosphorylation. Therefore, the basis for 
comparison was activated receptors at the cell surface (stimulated by EGF-beads) or within 
the cell (EGF stimulated).  
6.1 Studying of EGFR-mediated cell signaling with immobilized EGF 
The initial studies with immobilized EGF were not designed to study differences in EGFR 
signaling from the plasma membrane as compared to inside the cell. They were designed to 
understand how signaling was propagated at the plasma membrane. A study by Verveer et 
al. demonstrated that a liganded EGFR could propagate phosphorylation along the plasma 
membrane to other EGFRs that were not bound to a ligand (Verveer et al., 2000).  
The authors of this study used a microscopy-based assay that allowed the measure of 
receptor phosphorylation in real time. Briefly, cells expressing a green fluorescence protein 
(GFP)-tagged EGFR were microinjected with a Cyanine 3 (Cy3) labeled anti-
phosphotyrosine antibody. When the receptor is phosphorylated, the anti-phosphotyrosine 
antibody binds and places the Cy3 in close enough proximity (nanometers) to the GFP 
conjugated to EGF for fluorescent energy transfer (FRET). From these studies, it was 
concluded that both soluble EGF and EGF-beads could propagate signaling along the 
plasma membrane of cells. 
Secondary to the authors intent, this study demonstrated that EGF-beads could: 1) bind to 
the EGFR and 2) be retained at the plasma membrane. In addition to the insights about 
EGFR signal propagation provided by this study, it also provided an important foundation 
for future studies analyzing the temporal and spatial basis of EGFR signaling. 
A second study using EGF-beads, also took a single cell approach (Kempiak et al., 2003). The 
goal of this study was to assess the localized signaling of the EGFR using chemotaxis as the 
physiological readout. The authors demonstrate that EGF beads, like EGF, can induce a 
chemotactic response as visualized by video microscopy. Further, cell surface receptors 
could initiate the cell migration by triggering cytoskeletal reorganization as measured by 
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staining with rhodamine phalloidin. The authors examined selected signaling pathways and 
found that phosphorylation of Akt was about three time greater following treatment with 
EGF-beads as compared to EGF. 
It is worth re-stating that the goal of these two studies was not to distinguish cell surface 
versus intracellular EGFR signaling. Rather, both studies set up out to examine localized 
EGFR signals initiated from the plasma membrane. Therefore, they provide important 
information regarding cell surface receptor signaling, but are limited in what they reveal 
about what occurs within the cell. 
6.2 Using EGF immobilized to a solid support to study EGFR-mediated cell migration 
Although the EGF-beads are a useful way to study EGFR from the plasma membrane, 
variations on this theme have proven useful as well. Most notably, EGF that has been 
immobilized to the bottom of tissue culture dishes has proven to be an effective tool in 
studying cell migration. Bioengineering groups seeking to develop new methods for drug 
delivery performed these studies. Although EGFR is closely associated with the 
development of cancer, it has also been shown to be instrumental in wound healing and 
tissue homeostasis as well. Thus, cancer biologists should take notice of these engineering 
studies, as the tools developed for in vitro models of wound healing may provide important 
mechanistic insights into EGFR-mediated changes in cell biology and well as useful tools for 
studying the fundamental cell biology of the EGFR. 
Early studies by Chen et al. used covalently linked EGF to a polystyrene dish using photo 
irradiation. Briefly, EGF was coupled with N-(4-azidobenzoyloxy)succinimide and the 
resulting solution was coated on a polystyrene dish, and the water was allowed to evaporate. 
Ultraviolet light was used to crosslink the modified EGF to the dish (Chen et al., 1997).  
To test the new ligand, Chinese Hamster Ovary (CHO) cells or mouse fibroblasts were 
plated on top of the immobilized EGF and monitored for cell growth by 3H-thymidine 
incorporation. The rate of cell growth was approximately three fold higher with the 
immobilized EGF as compared to soluble EGF. 
A modification of this approach was used by Stefonek and Masters (Stefonek and Masters, 
2007). While these authors used the same basic model of immobilizing EGF to the bottom of 
a tissue culture dish, they did so with a concentration gradient. Using photo-patterning, 
precise control of the spatial localization of the EGF was achieved. Human keratinocytes 
(HaCaT cells) were plated on this EGF matrix and monitored for cell migration over the 
course of 16 days. These studies demonstrated that cells migrated toward the higher 
concentrations of immobilized EGF. Migration was approximately five fold greater than the 
control conditions. Both groups considered their findings to support the model that 
endocytosis negatively regulates EGFR signaling. Restricting endocytosis, prevents receptor 
degradation, and prolongs signaling, thereby enhancing cell migration.  
Our understanding of EGFR signaling is enhanced by these studies for several reasons. First, 
in both studies with immobilized EGF are looking at EGFR-mediated responses in large 
populations of cells, rather than events in one cell. In doing so, these studies lay the 
groundwork for providing a biochemical analysis of changes in signaling. Second, they 
examine changes in cell biology that are of interest to a cancer biologist. Cell migration and 
proliferation are two key EGFR-mediated signaling events that need to be attenuated in the 
successful treatment of cancer. Finally, as bioengineering groups, the authors introduce the 
biologists to ways of modifying ligands in a manner that does not compromise their biologic 
activity. 
www.intechopen.com
 
Endocytic Trafficking of the Epidermal Growth Factor Receptor in Transformed Cells 
 
65 
However, in terms of understanding the spatial and temporal regulation of signaling, these 
studies are limited in their scope. These studies provide evidence, at least in these 
physiological assays that indicate endocytosis is a negative regulator of signaling. This 
finding supports the original report by Wells et al, in which mutant, endocytosis resistant 
EGF were more potent and efficacious activator of cell transformation (Wells et al., 1990). 
However, it is not clear from these experiments whether all signaling pathways are 
enhanced or just a subset. Further, since all physiological responses being analyzed are 
enhanced, it is unclear whether some responses are positively regulated by endocytosis.  
6.3 A biochemical analysis of EGFR signaling using EGF-beads 
Work done by Hyatt and Ceresa combined the flexibility of EGF-beads with the biochemical 
analysis provided by immobilized EGF, to analyze EGFR signaling (Hyatt and Ceresa, 2008). 
This study, in contrast to the previous ones, specifically seeks to understand 1) whether 
EGFR signaling was spatially regulated, and 2) if so, how? Thus, in this work, the authors 
used EGF-beads to stimulate cells and examined cell physiology in response to activated 
EGFRs at the plasma membrane and within the cell. 
 
 
Fig. 5. Depiction of How Soluble EGF and EGF-beads elucidate Differences in EGFR 
Signaling. 
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MDA-MB-468 cells were used to study signaling by cell surface and intracellular receptors. 
MDA-MB-468 cells were first described by Cailleau et al, as part of a series of metastatic 
breast cancer cell lines derived at the MD Anderson Cancer Center in Houston, Texas 
(Cailleau et al., 1978). Cell lines derived from metastatic breast cancer tumors were examined 
for common features as well as for developing model systems for studying the cell biology 
of transformed cells. Despite a number of similarities, each cell line has some unique 
features. In the case of the MDA-MB-468 cells, one of its distinguishing features is the 
overexpression of EGFR. It is reported that MDA-MB-468 cells express ~ 1.3 x 106 
EGFRs/cell (Filmus et al., 1985). This is about 15-25 times what is regarded as a 
physiological level of receptors (50-100,000 EGFRs/cell).  
The high level of EGFRs makes it amenable for studying the spatial regulation of signaling 
for a number of reasons. First, the high levels of receptors provide a dynamic range of 
response following stimulation with ligand. This increases the signal-to-noise ratio. Second, 
cell lines with high levels of EGFR have slowed kinetics of endocytic trafficking. This has 
been demonstrated both in cell lines that naturally overexpress EGFR (i.e. cancer cell lines), 
as well as cells that have by stably transfected with receptors to increase their expression 
(French et al., 1994; Stoscheck and Carpenter, 1984). It is commonly held that the delay in 
trafficking is the result of saturation of the machinery that moves the ligand:receptor 
complex through the endocytic pathway. Regardless of the cause, the absence of appreciable 
receptor degradation facilitates analyzing the spatial regulation of signaling. In MDA-MB-
468 cells, any changes signaling that accompany retaining the activated EGFR at the plasma 
membrane must be due to the receptor’s location. 
In this paper, the first apparent difference in signaling by EGF and EGF-beads was a change 
in cell morphology. Cells were incubated with either ligand and examined by light 
microscopy. The differences in the cells were readily apparent. As had been reported by 
numerous other groups, treatment with EGF caused the induction of apoptosis that was 
characterized by the transition of cells from spread-out cobblestone morphology to one that 
was rounded up. In contrast, cell treated with EGF-beads, maintained a morphology that 
was indistinguishable from untreated cells.  
It is worth noting that EGF-mediated apoptosis is not is something that is commonly 
associated with EGFR signaling in the context of developmental biology, maintenance of 
healthy tissue, or cancer biology. However, among cell lines that overexpress the EGFR, 
such as MDA-MB-468 cells and A431 cells, EGF-mediated apoptosis has been well described 
(Armstrong et al., 1994; Gill and Lazar, 1981; Kottke et al., 1999; Tikhomirov and Carpenter, 
2004). Further, indirect evidence for the role of apoptosis in cancer biology has been 
suggested by Tikhomirov and Carpenter. They note that in the literature, more moderate 
levels of ErbB receptor tyrosine kinases are associated with more invasive carcinomas. They 
suggest that the induction of apoptosis in cell lines with higher levels of ErbB receptor 
expression generates a cancer cell whose growth and metastasis is self limiting (Tikhomirov 
and Carpenter, 2004). 
Of course, the easiest explanation for the differences in cell survival following EGF and 
EGF-bead treatment would be that the EGF-beads were not adequately stimulating the 
receptor. This was tested using both single cell and biochemical approaches. A time course 
of EGF-bead stimulation resulted in cells with anti-phosphoEGFR staining along the plasma 
membrane of the cell. This is evidence that 1) the EGFR was activated and 2) the EGFR was 
retained at the plasma membrane, two key features of the EGF-beads if a meaningful 
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analysis of signaling is to be made. Further, when cell lysates were prepared from EGF-
beads treated dishes of cells, a comparable level of EGFR phosphorylation was observed as 
seen with treatment with soluble EGF.  
These data provide evidence that endocytosis is required for the induction of apoptosis, 
however, it does not determine whether distinct signals are occurring at the plasma 
membrane. To answer this question, the authors measured cell proliferation as a function of 
3H-thymidine incorporation. In cells treated with soluble EGF, there was a dose dependent 
decrease in 3H-thymidine incorporation, which likely reflects the fact that the cells are 
undergoing apoptosis in response to EGF. Cells treated with EGF-beads had an 
approximately three-fold increase in 3H-thymidine incorporation.  
In addition, the authors demonstrate that intracellular, but not cell surface, EGFRs activate 
the caspase-3, an executioner caspase in the apoptotic pathway. Further, inhibition of 
caspase-3 prevents the induction of apoptosis, but does not enhance the proliferative effects 
of the cell surface EGFRs.  
Together, these data provide evidence that cell surface and intracellular EGFRs, not only 
signal differently, but the induce reciprocal effects. Often such reciprocal effects indicate an 
important regulatory mechanism in biology. This work stimulates a number of important 
questions. Can the induction of the EGFR-mediated apoptosis be engineered into a 
therapeutic treatment for cancer? What are the effector proteins being activated at the cell 
surface versus inside the cell? How are these differences in signaling manifest in cell lines 
with physiological levels of receptors? 
7. Future studies in the temporal and spatial regulation of EGFR signaling 
Over the last approximately 25 year, the complex relationship between EGFR signaling and 
membrane trafficking has been increasingly exposed. While it is widely accepted that 
endocytic trafficking can both positively and negatively regulate EGFR signaling, it remains 
unclear exactly to what extent. The field has faced technical limitations that accompany 
studying two dynamic processes. Further, since both processes branch out into multiple 
directions, the complexity increases. Through normal, physiological membrane trafficking, 
the EGFR can be found on the plasma membrane, in endosomes, lysosomes, the nucleus, 
and endoplasmic reticulum. Similarly, the activated EGFR can signal to multiple 
downstream effectors. Therefore, identifying which signaling events occur at which 
subcellular locations is anything but a trivial undertaking. 
Thus far, the most fruitful approaches have been ones that have attempted to disrupt or at 
least dramatically slow down endocytic trafficking. The myriad approaches have been 
discussed in this chapter. Essentially, these approaches allow the investigator to take a 
snapshot of signaling. Despite the caveats of such approaches, to date, it has proven to be 
the most effective strategy. 
Although tremendous progress has been made, it appears that we have only begun to 
understand how these processes come together much more needs to be done. For example, a 
more comprehensive map of EGFR:effector communication at the cell surface and within the 
cell. Definitively proving that a receptor:effector interaction occurs is a major undertaking, 
and requires substantial experimentation to establish such a model. To date, there are only a 
limited number of effectors whose activity has been studied. Although many of these 
effectors have well-established roles in EGFR signaling, this does not preclude the need to 
study other effectors. Further, a systematic analysis of plasma membrane versus 
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intracellular signaling for a large cohort of known EGFR effectors would be helpful for 
developing a model that predicts how receptor:effector communication occurs. 
Once cell surface versus intracellular EGFR signaling is established, signaling from various 
locations within the cell needs to be understood. At this point, the most effective strategy is 
to disrupt membrane trafficking at discrete endocytic stages, despite the aforementioned 
caveats. Geographically, it does not seem likely that receptors in early endosomes and on 
the limiting membrane of the late endosome, would have access to different subsets of 
cytosolic effectors. However, the effectors may differentially associate with the various 
endocytic compartments either directly or through adaptor proteins. Together this analysis 
will generate a temporal and spatial map of EGFR:effector interactions that may be useful 
for anticipating how cell physiology is regulated. 
In addition to delineating the receptor:effector interactions, another important question is 
whether the temporal/spatial regulation of EGFR:effector interaction is universal among all 
cell lines. This is a critical question because the EGFR mediates such a diverse array of 
physiological responses, endocytic regulation of EGFR signaling may provide important 
insight to explain the EGFR-dependent cell responses that are unique to a given cell line. This 
is particularly likely to be important in cancer cells that overexpress the EGFR. It is established 
that overexpression of the EGFR alters the endocytic trafficking of the EGFR and decreases the 
rate of receptor degradation. Since this effects both the duration and spatial placement of the 
activated receptor, it is reasonable to predict that there would be changes in signaling as well.  
Ultimately, our goal for understanding the molecular basis of EGFR signaling is rooted in 
developing strategies for the pharmacological manipulation of signalling pathways. 
Knowing how the signaling pathways are regulated has a number of uses. First, 
understanding how each effector is activated will provide a better understanding of its 
contribution to a give cell physiology. Thus, the effector activity can be modulated 
downstream of the effector. Second, the endocytic pathway itself may be a useful target. 
Disrupting or accelerating endocytic trafficking may be sufficient to achieve desired changes 
in cell biology. Finally, an effort to study this regulation of signaling in vivo is necessary. 
Dissecting the in vivo regulation will not only help in develop anti-cancer therapeutics but 
also in other EGFR-mediated physiologies, such as wound healing. 
8. Conclusion 
Overexpression and hyperactivation of the EGFR as associated with many cancers. While 
inhibitors against the EGFR are effective for some EGFR-positive cancers, they are not 
effective in the treatment of breast cancers. In order to develop therapeutic agents to treat 
EGFR-positive breast cancers, a more thorough analysis of EGFR is needed, in particular, 
insight into how its signaling is regulated. Discussed here is the role of the endocytic 
pathway in controlling the duration and specificity of EGFR signaling. This field has made 
grade strides in understanding the relationship between the two processes. The basic science 
that underlies these studies has important implications in developing new tools for the 
detection, diagnosis, and treatment of breast cancers with elevated levels of the EGFR. 
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